CMS Open Payments · Program Year 2024
Gyrus ACMI, Inc.
Gyrus ACMI, Inc. reported $738,606.41 across General Payments, Research, and Ownership to 91 physicians and teaching hospitals across 142 transactions.
- $738.6K
- All-tracks total
- 142
- Transactions
- 91
- Recipients
- +$219.5K
- General Payments vs PY2023
Gyrus ACMI, Inc. reported $738,606.41 across all CMS Open Payments tracks (General + Research + Ownership) to 91 physicians and teaching hospitals in Program Year 2024 - ranking #686 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $303,988.90, averaging $8.1K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer gyrus-acmi-inc Gyrus ACMI, Inc.
$738.6K · #686/1,925 · 0.0% industry · PY2024
- TOT $738.6K
- RANK #686
- SHARE 0.0%
- TXN 142
- RCP 91
- CAT 7
- GEN $304.0K
- ΔGEN +$219.5K
- TOP1 71.9%
- PY 2024
Volume peers
Nearest volume peer: Intera Oncology, Inc ($739.7K)
Gyrus ACMI, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Gyrus ACMI, Inc.'s CMS-reported General Payments increased by $219.5K (+259.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GYRUS ACMI, INC.PY2023: GYRUS ACMI, INC.PY2024: Gyrus ACMI, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $84,521.26
- PY2024
- $303,988.90
What the Data Shows for Gyrus ACMI, Inc.
Rank #686 of 1,925 companies in CMS Open Payments for 2024 belongs to Gyrus ACMI, Inc., which reported $738,606.41 across 142 transactions to 91 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $5.2K per transaction and $8.1K per recipient.
5 transactions worth $119.3K make "Space Rental or Facility Fees" the top general-payment category in the 7-category breakdown below, 39.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 7 types of general payments, Gyrus ACMI, Inc.'s largest category was "Space Rental or Facility Fees" at $119.3K - 39.2% of General Payments.
Gyrus ACMI, Inc. reports 7 general-payment categories - the top three are Space Rental or Facility Fees (39.2%), Education (32.6%), and Consulting Fee (16.7%). The remaining 4 categories make up 11.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Gyrus ACMI, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Space Rental or Facility Fees | $119.3K | 5 | 39.2% |
| Education | $99.2K | 2 | 32.6% |
| Consulting Fee | $50.9K | 44 | 16.7% |
| Debt Forgiveness | $20.6K | 5 | 6.8% |
| Royalty or License | $11.0K | 16 | 3.6% |
| Travel and Lodging | $2.7K | 12 | 0.9% |
| Food and Beverage | $294.91 | 7 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $276,785.79 (91.1%) of $303,988.90 in this company's General Payments records across 37 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Gyrus ACMI, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Tufts Medical Center
$218,475.70 across 7 reported transactions
- 2
Newark Beth Israel Medical Center
$19,560.00 across 1 reported transactions
- 3
Momen Wahidi
$16,096.98 across 16 reported transactions
- 4
Alexander C Chen
$13,872.65 across 14 reported transactions
- 5
Robert Goldenberg
$8,780.46 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Gyrus ACMI, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Gyrus ACMI, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Gyrus ACMI, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
OPKO Pharmaceuticals, LLC
Cardiva Medical, Inc.
La Jolla Pharmaceutical Company
TightLine Development, LLC
Carl Zeiss Meditec USA, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.